

AD _____

Award Number: DAMD17-01-1-0427

TITLE: Celecoxib in Women at Increased Breast Cancer Risk

PRINCIPAL INVESTIGATOR: Edward R. Sauter, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Missouri-Columbia
Columbia, Missouri 65212

REPORT DATE: October 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030313 146

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2002	3. REPORT TYPE AND DATES COVERED Annual (1 Oct 01 - 30 Sep 02)	
4. TITLE AND SUBTITLE Celecoxib in Women at Increased Breast Cancer Risk			5. FUNDING NUMBERS DAMD17-01-1-0427	
6. AUTHOR(S) Edward R. Sauter, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Missouri-Columbia Columbia, Missouri 65212 E-Mail: sautere@health.missouri.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Cyclooxygenase (COX)-1 and COX-2, are present in breast tumors and catalyze the conversion of arachadonic acid to prostaglandins. Prostaglandin E2 (PGE ₂) has tumor and cell growth promoting activity, and is overexpressed in human breast cancer. We proposed a pilot study of celecoxib administered to women at increased breast cancer risk, defined as a projected 5 year Gail model risk of invasive breast cancer > 1.66%, as well as women with a history of ductal carcinoma in situ or invasive breast cancer. Our hypothesis is that celecoxib will be concentrated in breast fluid compared to corresponding plasma, and that it will decrease PGE ₂ levels in nipple aspirate fluid (NAF) and in plasma. Our Specific Aims are to determine if 1) celecoxib is delivered to the breast, and 2) PGE ₂ levels in NAF and plasma increase after a 2 week course of celecoxib, then return to baseline 2 weeks after stopping the medication. Both pre- and postmenopausal women undergo nipple aspiration and blood draw three times: before, 2 weeks after starting celecoxib, and 2 weeks after stopping the medication. Each woman serves as her own control. Thus far we have enrolled 11 women on trial. NAF has been collected successfully in all subjects at each time point. PGE ₂ levels were measurable in all NAF samples, and were significantly higher in NAF than in matched plasma. During the coming year, we hope is to determine if PGE ₂ levels significantly decrease after celecoxib administration, and if they return to baseline 2 weeks after discontinuing medication.				
14. SUBJECT TERMS breast cancer, nipple aspirate fluid, celebrex (celecoxib), prostaglandin E2, cyclooxygenase inhibitor			15. NUMBER OF PAGES 5	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	5
Appendices.....	5

INTRODUCTION

Cyclooxygenase (COX)-1 and COX-2 enzymes are present in breast tumors and convert arachadonic acid to prostaglandins. Prostaglandin E2 (PGE2) has tumor and cell growth promoting activity. Nonsteroidal anti-inflammatory medications inhibit both COX-1 and COX-2. Inhibition of COX-1 leads to a number of side effects, including gastrointestinal ulcers and renal toxicity. The attractiveness of COX-2 inhibitors is that they appear to be effective in both preventing and treating a wide variety of human tumors, yet have a very favorable toxicity profile. Celecoxib, for example, has been administered to thousands of people.

We are able to collect breast nipple aspirate fluid (NAF) noninvasively using a modified breast pump from > 99% of nonlactating adult females. The fluid contains breast epithelial cells, which give rise to breast cancer, as well as proteins and other molecules secreted from the ductal epithelium. It is our hypothesis that the expression of COX-2 and PGE2 in NAF will decrease in women at increased risk for breast cancer after a two week course of celecoxib.

Recent publications provide support for the hypothesis that an inhibitor of COX-2 would be effective in to prevent and treat breast cancer. The currently available generally accepted treatments for women at high breast cancer risk are limited to tamoxifen vs. observation. While effective, tamoxifen presents the potential risks of pulmonary embolism and uterine cancer. We propose a novel method to evaluate biomarkers of therapeutic efficacy using a safe, well tolerated medication which shows promise in the prevention of breast cancer.

BODY

Task 1. Enroll subjects on the trial.

- A. Notify physicians at the University of Missouri-Columbia (UMC) and its Network Hospitals that the study has begun (Months 1-3).

I have moved to the UMC and informed USAMRMC of this. I have completed the task above.

- B. Enroll subjects for initial and repeat aspirations (Months 1-34).

11 subjects have been enrolled. Nipple aspirations have been collected from 11 subjects, and 8 subjects have completed the study.

- C. Work with data management programmers to establish data entry files (Months 1-6).

Done.

Task 2. Assess drug delivery and effect

- A. Begin evaluation of NAF and plasma specimens. Evaluate NAF and plasma levels of COX-2 and PGE₂ (Months 3-34).

NAF and plasma levels of PGE₂ have been analyzed in ___ specimens (see results below). Since we batch these, we will soon send another groups of specimens for analysis. COX-2 analysis is done by an outside company where batching is essential to lower costs. We have therefore not yet sent samples for COX-2 analysis.

- B. Finalize the analysis of specimens. Compare results in baseline vs. treated vs. washout period samples (Months 33-35).

This task will be performed later.

Table 1

PGE₂ (ng/ml) Levels in NAF and Plasma

	Samples with Measurable PGE ₂	Range	Median
NAF	6/6	1.97-4.23	2.09
Plasma	0/6 (level < 0.1 ng/ml)		

There are insufficient samples to assess the effect of celecoxib on PGE₂.

NAF PGE₂ was measurable before and after celecoxib administration.

KEY RESEARCH ACCOMPLISHMENTS

- Collection of NAF and plasma from 11/34 projected subjects
- Successful analysis of PGE₂ in NAF from all samples tested
- There has been no significant toxicity
- No subject has withdrawn from the study

REPORTABLE OUTCOMES

Statistical analysis of our results is premature.

CONCLUSIONS

The research conducted thus far indicates that 1) celecoxib is well tolerated in this subject population, 2) celecoxib does not inhibit our ability to collect NAF, 3) we can successfully recruit subjects to this trial and 4) we can analyze NAF specimens for PGE₂, and 4) plasma levels are below the sensitivity of our assay, 0.1 ng PGE₂/ml sample.

REFERENCES: N/A

APPENDICES: N/A